Host Determinants of Infectiousness in Smear-Positive Patients With Pulmonary Tuberculosis
- PMID: 31205972
- PMCID: PMC6557197
- DOI: 10.1093/ofid/ofz184
Host Determinants of Infectiousness in Smear-Positive Patients With Pulmonary Tuberculosis
Abstract
Background: Epidemiologic data suggests that only a minority of tuberculosis (TB) patients are infectious. Cough aerosol sampling is a novel quantitative method to measure TB infectiousness.
Methods: We analyzed data from three studies conducted in Uganda and Brazil over a 13-year period. We included sputum acid fast bacilli (AFB) and culture positive pulmonary TB patients and used a cough aerosol sampling system (CASS) to measure the number of colony-forming units (CFU) of Mycobacterium tuberculosis in cough-generated aerosols as a measure for infectiousness. Aerosol data was categorized as: aerosol negative (CFU = 0) and aerosol positive (CFU > 0). Logistic regression models were built to identify factors associated with aerosol positivity.
Results: M. tuberculosis was isolated by culture from cough aerosols in 100/233 (43%) TB patients. In an unadjusted analysis, aerosol positivity was associated with fewer days of antituberculous therapy before CASS sampling (p = .0001), higher sputum AFB smear grade (p = .01), shorter days to positivity in liquid culture media (p = .02), and larger sputum volume (p = .03). In an adjusted analysis, only fewer days of TB treatment (OR 1.47 per 1 day of therapy, 95% CI 1.16-1.89; p = .001) was associated with aerosol positivity.
Conclusion: Cough generated aerosols containing viable M. tuberculosis, the infectious moiety in TB, are detected in a minority of TB patients and rapidly become non-culturable after initiation of antituberculous treatment. Mechanistic studies are needed to further elucidate these findings.
Figures
References
-
- World Health Organization. Global tuberculosis report 2018. WHO/HTM/TB/2018.23. Geneva, Switzerland: World Health Organization; 2018. Available at: www.who.int/tb/publications/global_report/en/.
-
- Uplekar M, Weil D, Lonnroth K, et al. ; for WHO’s Global TB Programme WHO’s new end TB strategy. Lancet 2015; 385:1799–801. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
